News Releases

 
News Releases
  Date Title and Summary View
Dec 5, 2001
NEW ORLEANS, Nov. 14 -- Cordis Cardiology reported today U.S. market introduction of its new Bx VELOCITY(TM) Coronary Stent with Hepacoat(TM) -- the first drug-coated stent utilizing a proprietary heparin coating to receive regulatory approval in the U.S. and Europe. Cordis Cardiology is a unit of Cordis Corporation, a Johnson & Johnson company. ...
Dec 5, 2001
ANAHEIM, Calif., Nov. 13-- Pilot clinical results to be presented today at annual scientific sessions of the American Heart Association show the potential for Cordis Corporation's CYPHER(TM) Sirolimus-eluting Stent to markedly reduce in-stent restenosis in patients with coronary artery disease. Funded by a grant from Cordis, the ISR (In-Sten...
Nov 21, 2001
Johnson & Johnson to Participate in The Second Annual Merrill Lynch Med Tech Fundamentals Conference NEW BRUNSWICK, N.J., Nov 21, 2001 -- Johnson & Johnson will participate in The Second Annual Merrill Lynch Med Tech Fundamentals Conference at the Metropolitan Club in New York on Wednesday, November 28, 2001. There will be panel presentatio...
Nov 21, 2001
NEW BRUNSWICK, N.J., Nov 21, 2001 -- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, today announced the completion of its previously announced acquisition of Inverness Medical Technology, excluding certain businesses. The transaction was completed today after Inverness sharehold...
Nov 19, 2001
NEW BRUNSWICK, N.J., Nov. 16-- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, announced today that its proposed acquisition of Inverness' diabetes care products business and the split-off of Inverness' women's health, nutritional supplements and clinical diagnostics businesses a...
Nov 5, 2001
NEW YORK STOCK EXCHANGE--Ringing the opening bell at the NYSE to celebrate the 12th anniversary of Johnson & Johnson-Merck Consumer Pharmaceuticals Co. and the launch of new Pepcid® Complete, the first and only fast and long-lasting heartburn remedy, will be Peter K. Miller, President of Johnson & Johnson-Merck Consu...
Oct 25, 2001
NEW BRUNSWICK, N.J., Oct. 25 -- Johnson & Johnson (NYSE: JNJ) today announced the signing of an agreement to buy the 40 percent equity stake in its Japanese pharmaceutical joint venture, Janssen-Kyowa Co., Ltd., held by its Japanese partner, Kyowa Hakko Kogyo Co., Ltd. The terms of the agreement were not disclosed. Johnson & Johnson has owned ...
Oct 24, 2001
NEW BRUNSWICK, N.J., Oct 24, 2001 that it is seeking FDA permission to add anthrax as an approved indication for its broad-spectrum anti-infective, LEVAQUIN. The company said it is prepared to make available up to 100 million tablets free of charge to the Federal government for use as it determines appropriate, assuming FDA approval. The comp...
Oct 22, 2001
NEW BRUNSWICK, N.J. and WALTHAM, Mass., Oct 22, 2001 -- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, and Inverness Medical Technology (Amex: IMA), a developer of innovative products focused primarily on the self-management of diabetes, today announced that the Securities and E...
Oct 16, 2001
NEW BRUNSWICK, N.J., Oct. 16 -- Johnson & Johnson today announced sales of $8.2 billion and net earnings of $1.5 billion for the third quarter of 2001, increases of 10.8% and 15.6%, respectively, over third quarter 2000 results. Diluted earnings per share for the third quarter were $.49, up 14.0% from the same period in 2000. Excluding the impact o...
Page:
1
... NextLast
= add release to Briefcase